Explore/PYY 3-36 Compound Profile

PYY 3-36 Compound Profile

Fat Loss / Metabolic • Peptide

◐ Emerging EvidenceResearch Only
Evidence
Weak3/10
Hype
Moderate4/10
Risk
Low3/10
Beginner Friendly
Moderate4/10

Plain English Summary

PYY 3-36 is a peptide derived from the pro-peptide form of peptide YY (PYY), primarily secreted by the ileum in response to food intake. It plays a crucial role in regulating appetite, energy homeostasis, and metabolic processes. Emerging research highlights its therapeutic potential in obesity management and opioid use disorders.

What People Use It For

Weight managementAppetite regulationMetabolic healthReducing opioid-seeking behavior

Side Effects & Risks

Common Side Effects

Possible gastrointestinal discomfortUnknown long-term effectsLimited side effect data due to research stage

References

  • 1https://pubmed.ncbi.nlm.nih.gov/28003328/
  • 2https://pubmed.ncbi.nlm.nih.gov/37572954/
  • 3https://pubmed.ncbi.nlm.nih.gov/37001706/
  • 4https://pubmed.ncbi.nlm.nih.gov/40629530/
  • 5https://pubmed.ncbi.nlm.nih.gov/22975597/
  • 6https://pubmed.ncbi.nlm.nih.gov/38542814/
  • 7https://pubmed.ncbi.nlm.nih.gov/26006332/
  • 8https://pubmed.ncbi.nlm.nih.gov/34272643/

Researchers also explore

Semaglutide

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most effective weight loss medications available. It works by mimicking a natural hormone that regulates appetite and blood sugar, helping people feel full faster and longer.

View

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even stronger weight loss results than semaglutide in clinical trials. It targets two hormone pathways instead of one, making it potentially more effective for both weight loss and blood sugar control.

View

GIP (Glucose-dependent Insulinotropic Polypeptide)

GIP is an endogenous incretin hormone released from the gut after nutrient intake. It plays a critical role in glucose metabolism by stimulating insulin secretion in a glucose-dependent manner. While historically studied for its insulinotropic effects, modern research focuses on its systemic roles in adipose tissue, bone remodeling, and the central nervous system, particularly when combined with GLP-1 for metabolic therapies.

View

Glucose-dependent insulinotropic polypeptide (GIP)

GIP is an incretin hormone secreted by the intestine that plays a key role in glucose metabolism and energy homeostasis. While traditionally recognized for its role in stimulating insulin secretion in response to nutrient intake, recent research highlights its involvement in lipid metabolism, bone health, and neurological function. It is currently a focal point of therapeutic development in combination with GLP-1 agonists for treating obesity and metabolic disease.

View

Researcher Sentiment

No votes yet — be the first

Educational Content Only

This is not medical advice. Always consult a licensed healthcare provider before using any compound. No dosing or sourcing guidance is provided.